Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II–III Systolic Heart Failure

The NLRP3 inflammasome has been implicated in the development and progression of heart failure. The aim of this study was to determine the safety of an oral inhibitor of the NLRP3 inflammasome, dapansutrile (OLT1177), in patients with heart failure and reduced ejection fraction (HFrEF). This was a p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wohlford, George F., Van Tassell, Benjamin W., Billingsley, Hayley E., Kadariya, Dinesh, Canada, Justin M., Carbone, Salvatore, Mihalick, Virginia L., Bonaventura, Aldo, Vecchié, Alessandra, Chiabrando, Juan Guido, Bressi, Edoardo, Thomas, Georgia, Ho, Ai-Chen, Marawan, Amr A., Dell, Megan, Trankle, Cory R., Turlington, Jeremy, Markley, Roshanak, Abbate, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Journal of Cardiovascular Pharmacology 2021
Materias:
Drugs in the Pipeline: Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774821/
https://www.ncbi.nlm.nih.gov/pubmed/33235030
http://dx.doi.org/10.1097/FJC.0000000000000931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774821/
https://www.ncbi.nlm.nih.gov/pubmed/33235030
http://dx.doi.org/10.1097/FJC.0000000000000931

Ejemplares similares